We are live on
!
Find out more
Ensign Peak Advisors Portfolio holdings
AUM
$53.7B
1-Year Est. Return
29.47%
This Fund
S&P 500
This Quarter
Est. Return
+13.33%
1 Year Est. Return
+29.47%
3 Year Est. Return
+102.45%
5 Year Est. Return
+139.11%
10 Year Est. Return
–
AUM
$54.8B
AUM Growth
+$4.24B
(+8.4%)
Cap. Flow
-$502M
Cap. Flow
% of AUM
-0.92%
Top 10 Holdings %
Top 10 Hldgs %
29.94%
Holding
1,776
New
37
Increased
449
Reduced
1,142
Closed
51
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$158M |
| 2 |
Uber
UBER
|
+$110M |
| 3 |
Blackstone Secured Lending
BXSL
|
+$97.3M |
| 4 |
Amazon
AMZN
|
+$76.3M |
| 5 |
PayPal
PYPL
|
+$75.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$184M |
| 2 |
Crown Castle
CCI
|
+$173M |
| 3 |
CME Group
CME
|
+$125M |
| 4 |
Gilead Sciences
GILD
|
+$119M |
| 5 |
Amgen
AMGN
|
+$115M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.81% |
| 2 | Healthcare | 15.16% |
| 3 | Financials | 13.11% |
| 4 | Consumer Discretionary | 9.82% |
| 5 | Communication Services | 8.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1676
RxSight
RXST
$233M
| $361K | ﹤0.01% |
+6,997
| New | +$343K |
|
1677
Navitas Semiconductor
NVTS
$2.78B
| $350K | ﹤0.01% |
73,445
-3,705
| -5% | -$21.8K |
|
|
NFBK
1678
DELISTED
Northfield Bancorp
NFBK
| $344K | ﹤0.01% |
35,413
-1,787
| -5% | -$19.6K |
|
|
RVNC
1679
DELISTED
Revance Therapeutics, Inc.
RVNC
| $331K | ﹤0.01% |
67,332
+16,982
| +34% | +$101K |
|
1680
Kanzhun
BZ
$7.03B
| $329K | ﹤0.01% |
18,750
| – | – |
|
1681
MarineMax
HZO
$799M
| $326K | ﹤0.01% |
9,809
+146
| +2% | +$4.68K |
|
1682
OraSure Technologies
OSUR
$273M
| $323K | ﹤0.01% |
52,519
-2,649
| -5% | -$19.2K |
|
1683
ImmunityBio
IBRX
$7.32B
| $320K | ﹤0.01% |
+59,650
| New | +$270K |
|
1684
Aurinia Pharmaceuticals
AUPH
$1.96B
| $319K | ﹤0.01% |
63,735
-3,215
| -5% | -$21.8K |
|
1685
Great Southern Bancorp
GSBC
$863M
| $316K | ﹤0.01% |
5,759
-291
| -5% | -$15.5K |
|
1686
Bristow Group
VTOL
$1.37B
| $315K | ﹤0.01% |
11,591
-585
| -5% | -$15.6K |
|
|
CNH
1687
CNH Industrial
CNH
$13.7B
| $315K | ﹤0.01% |
24,300
+5,850
| +32% | +$70.8K |
|
1688
Usana Health Sciences
USNA
$412M
| $313K | ﹤0.01% |
6,445
-325
| -5% | -$15.9K |
|
|
TBI
1689
Trueblue
TBI
$237M
| $311K | ﹤0.01% |
24,802
-1,251
| -5% | -$16.2K |
|
1690
James River Group Holdings
JRVR
$217M
| $297K | ﹤0.01% |
31,986
-1,614
| -5% | -$14.8K |
|
1691
Lightwave Logic
LWLG
$945M
| $297K | ﹤0.01% |
63,402
-3,198
| -5% | -$13.9K |
|
|
FLNA
1692
Filana Therapeutics
FLNA
$43.5M
| $295K | ﹤0.01% |
14,546
-734
| -5% | -$16.9K |
|
1693
Applied Digital
APLD
$7.54B
| $292K | ﹤0.01% |
+68,210
| New | +$344K |
|
1694
Forward Air
FWRD
$466M
| $285K | ﹤0.01% |
9,147
-461
| -5% | -$19.3K |
|
1695
Beyond Meat
BYND
$283M
| $280K | ﹤0.01% |
33,843
-1,707
| -5% | -$13.1K |
|
1696
Embecta
EMBC
$204M
| $267K | ﹤0.01% |
20,115
-1,015
| -5% | -$15.7K |
|
1697
Nu Skin
NUS
$250M
| $253K | ﹤0.01% |
18,326
-924
| -5% | -$14.4K |
|
1698
MaxCyte
MXCT
$109M
| $247K | ﹤0.01% |
59,013
-2,977
| -5% | -$14K |
|
|
PETQ
1699
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $244K | ﹤0.01% |
13,340
-630,074
| -98% | -$11.2M |
|
1700
Symbotic
SYM
$5.28B
| $234K | ﹤0.01% |
+5,203
| New | +$228K |
|
Similar funds
SCP
Ensign Peak Advisors's Q1 2024 Portfolio in Review
As of Q1 2024, Ensign Peak Advisors held 1,776 positions worth $54.8B, up 8.4% from $50.5B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Trading was light in Q1 2024: portfolio turnover was 5%. Ensign Peak Advisors opened 37 new positions and exited 51, leaving the 1,776-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
- Ensign Peak Advisors's largest Q1 2024 buy was Blackstone Secured Lending: 3,319,725 shares worth $103M.
- Ensign Peak Advisors added most to Eli Lilly in Q1 2024, an estimated $158M increase.
- Ensign Peak Advisors's biggest Q1 2024 reduction was Vertex Pharmaceuticals, cutting an estimated $184M.
- Ensign Peak Advisors fully exited State Street SPDR S&P 500 ETF Trust in Q1 2024, selling an estimated $66.5M.
- Ensign Peak Advisors's ten largest holdings make up 30% of its $54.8B portfolio in Q1 2024.
- Ensign Peak Advisors opened 37 new positions and closed 51 in Q1 2024.
- Ensign Peak Advisors's portfolio value rose 8.4% quarter-over-quarter to $54.8B.
Based on Ensign Peak Advisors's 13F filing for Q1 2024, filed 14 May 2024.